Tailoring Head and Neck Cancer Therapy: Insights from the 3D-OTC Model in vitro - Takeaways - MDSpire

Tailoring Head and Neck Cancer Therapy: Insights from the 3D-OTC Model in vitro

  • By

  • Fabian Stögbauer

  • Tobias Weiser

  • Ali Bashiri Dezfouli

  • Johannes Wirth

  • Luca Engelmann

  • Jan Budczies

  • Iordanis Ourailidis

  • Melanie Boxberg

  • Katharina Pigorsch

  • Benedikt Schmidl

  • Nicole Strittmatter

  • Katja Steiger

  • Carolin Mogler

  • Barbara Wollenberg

  • April 25, 2026

  • 0 min

Share

  • 1

    Head and neck squamous cell carcinoma (HNSCC) treatment is challenging due to heterogeneous responses and lack of reliable biomarkers.

  • 2

    The 3D organotypic tissue co-culture (3D-OTC) model preserves tumor morphology and immune interactions, enhancing therapeutic testing.

  • 3

    The 3D-OTC model can be cultured for up to 21 days and accommodates both HPV-negative and HPV-positive tumor samples.

  • 4

    This study aims to evaluate the morphological and transcriptomic comparability of the 3D-OTC model to primary tumor tissue.

  • 5

    Findings may establish the 3D-OTC model as a platform for personalized therapeutic evaluation in HNSCC.

Original Source(s)

Tailoring Head and Neck Cancer Therapy: Insights from the 3D-OTC Model in vitro

  • by Fabian Stögbauer, Tobias Weiser, Ali Bashiri Dezfouli, Johannes Wirth, Luca Engelmann, Jan Budczies, Iordanis Ourailidis, Melanie Boxberg, Katharina Pigorsch, Benedikt Schmidl, Nicole Strittmatter, Katja Steiger, Carolin Mogler, Barbara Wollenberg

  • April 25, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma